NOVO NORDISK A/S
Last · XETRA€34.33-0.04 (-0.12%)live · yahoo · 4h ago
Market cap€151.5B3.34B sh
P/E · TTM9.8fwd — · eps 3.52
Beta0.38vs S&P 500
Div yield34.04%annual · TTM
52w range
€30.23€54.87
Volume24.1Ksession
| Revenue | DKK 175.3B |
|---|---|
| Operating income | DKK 86.7B |
| Net income | DKK 69.5B |
| Free cash flow | DKK 55.3B |
| Operating margin | 49.4% |
| Net margin | 39.7% |
| Return on equity | 31.4% |
| Period | 2026 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-09-02
- Current Ratio Low
Red flags
- Current Ratio Low — Current ratio 0.87
Upcoming earnings
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
—
Est. revenue
73.2B
Earnings transcripts
Press & signals
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
- Satelight
Can weight-loss drugs lose their nasty side effects?
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags